2021 Volume 32 Issue 1 Pages 111-117
Coronavirus disease 2019 (COVID-19) has been reported to be associated with a high incidence of venous thromboembolism (VTE). In Japan, a joint survey was conducted by the Japanese Society of Phlebology and the Japanese Society of Pulmonary Embolism Research, and a joint survey by the Japanese Society on Thrombosis and Hemostasis, the Japan Atherosclerosis Society, and the Ministry of Health, Labour and Welfare Research Group. Overall, the proportion of cases diagnosed with VTE was lower than that reported from other countries. On the other hand, it was suggested that there may be a reasonable incidence in severe cases. Currently, several randomized controlled trials are underway to evaluate the significance of anticoagulation for COVID-19 patients, and the results of these trials are expected to be useful in Japan. However, since the actual situation may differ from that in other countries, it is important to proceed with discussions based Japan’s own data. It is also necessary to prepare clinical guidelines based on continuously updated data, assuming that the latest updates and revisions are made sequentially, so as avoid confusion in clinical practice.
